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Summary
Background: Vaccination against hepatitis B virus (HBV) has been recommended for all high-risk
adults since 1982. Since the advent of highly active antiretroviral therapy, few studies have
examined adherence to the Infectious Diseases Society of America (IDSA) and Advisory Committee
on Immunization Practices (ACIP) guidelines for hepatitis B vaccination in persons infected with HIV.
Methods: This was a seven-year retrospective, cross-sectional analysis of HBV vaccination prac-
tices in HIV-1-positive adults treated in an urban ambulatory care center. Compliance with
screening, hepatitis B vaccination recommendations, and response to vaccination were assessed.
Results: Of the 1601 charts reviewed, 717 persons were eligible for vaccination against hepatitis B.
Of these patients, 503 received at least one dose of vaccine, but only 356 patients completed the
three-dose series. Vaccine response was associated with CD4 count (p = 0.006) and viral load
(p = 0.001) at the time of the first dose. However, development of hepatitis B surface antibody was
seen at all CD4 counts and viral loads. The multivariate analysis showed only the HIV viral load was
predictive of immunologic response. Twenty of the vaccine-eligible patients who did not receive
vaccination were infected with HBV during the study period. No vaccinated persons contracted
hepatitis B.
Conclusion: Failure to implement these guidelines represents a missed opportunity to prevent
disease. In our study, HIV viral load was better than CD4 count as a predictor of response to the HBV
vaccination. However, neither low CD4 count nor high HIV viral load should be used as justification
to delay vaccination of high-risk persons.
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Since the adoption of universal vaccination of newborns and
adolescents in 1991, overall new hepatitis B infection rates
have dropped dramatically. New infections currently are seen
primarily in high-risk adults. In the Centers for DiseasePublished by Elsevier Ltd. All rights reserved.
Figure 1 Results of screening and HBV vaccination.
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51 000 new infections and an estimated 1.2 million people
in the USAwith chronic hepatitis B infection. Of these, 4000—
5000 people will die each year from hepatitis B virus (HBV)-
related liver disease.1,2
Both the United States Public Health Service (USPHS)/
Infectious Diseases Society of America (IDSA) and the Advi-
sory Committee on Immunization Practices (ACIP) currently
recommend screening for HBV and vaccination for all adults
at increased risk for infection due to occupational, beha-
vioral, social, or medical reasons. These risk groups include
persons infected with HIV, healthcare workers, menwho have
sex with men (MSM), injection drug users, heterosexuals with
sexually transmitted diseases, household and sexual contacts
of HBV carriers, morticians, and incarcerated persons.2,3 In
2005, 79% of new HBV infections were associated with either
high-risk sexual behaviors and/or intravenous drug use
(IVDU).2
For persons at risk for suboptimal response to the HBV
vaccine, such as those with HIV infection, hepatitis B surface
antibody (HBsAb) levels should be checked within 6months of
completion of the vaccination series. Currently, it is not
recommended to vaccinate persons with isolated hepatitis
B core antibody (HBcAb) positivity.2—4
Adherence to these guidelines for HIV-infected patients
has not been well studied. One recent review of screening
and vaccination practices for hepatitis A and hepatitis B virus
in an HIV outpatient population, found low screening and
vaccination rates even among providers experienced in treat-
ing HIV.5 Studies done to evaluate the immunogenicity of the
hepatitis B vaccine in persons infected with HIV have had
varying results.5—8
This study reviews the screening and adherence to HBV
vaccination guidelines and immunologic outcomes in a large
inner city adult HIV primary care clinic. We evaluated a
number of variables to determine their significance for
immunologic response to the HBV vaccine.
Methods
We performed a seven-year (September 1997—September
2004) retrospective, cross-sectional cohort study of all HIV-
positive adults seen in an urban, inner city, primary HIV care
clinic. Institutional review board approval was obtained prior
to review of charts. Demographic data were collected,
including age, sex, weight, income level, and race. Other
data collected included CD4 count and HIV viral load at time
of first vaccine dose, use of highly active antiretroviral
therapy (HAART), smoking history, HBsAb and hepatitis B
surface antigen (HBsAg), isolated hepatitis B core antibody
(HBcAb), hepatitis Be antigen (HBeAg) and antibody (HBeAb),
hepatitis C co-infection, number of vaccine doses received,
time from seronegative study eligibility determination to the
time the first dose of vaccine was given, and reason for not
completing the vaccine series, if available. All persons were
screened prior to administration of HBV vaccine. HAARTwas
defined as three or more antiretroviral drugs, including at
least one protease inhibitor or non-nucleoside reverse tran-
scriptase inhibitor plus two other agents.
Exclusion criteria for vaccine eligibility included persons
who tested positive for HBsAb, HBsAg, and/or HBeAb. Persons
seropositive for isolated HBcAb were also considered ineli-gible, as the current guidelines do not support vaccination
(Figure 1). No patient had a hepatitis B viral load performed.
Each patient was followed for aminimum of one year after
their initial clinic visit for screening and initiation of the HBV
vaccination series. Patients were given the standard dose of
recombinant hepatitis B vaccine, either Engerix-B (GlaxoS-
mithKline) or Recombivax-HB (Merck). Patients were consid-
ered vaccine responders if their HBsAb levels were tested and
were greater than 10 mIU/ml.
SAS software packages (SAS institute, version 9.1) were
used for statistical analysis. The Pearson’s Chi-square test, the
two-sided Fisher’s exact test, and the Wilcoxon rank sum test
were used to compare the categorical and continuous vari-
ables, respectively, between the two subject groups. p-Values
less than 0.05 were considered significant. In the multivariate
stepwise regressionanalysis, variableswereanalyzed todeter-
mine independent risk factors for vaccine failure. The vari-
ables tested included age, sex, race, weight, use of HAART,
hepatitis C co-infection, CD4 count, and HIV viral load.
Results
A total of 1601 charts were reviewed, of which 25 were
excluded due to missing data or being out of the time range
of the study period. The remaining 1576 charts were included
in the study. Demographically, 69% of the patients weremale,
68% were African-American, 54.7% were diagnosed with HIV,
not AIDS, and 58% lived below the level of poverty (Table 1).
Risk factors for HIV and HBV infection included homosexual
activity (23%), IVDU (10%), heterosexual activity (39%), and
healthcare-associated (2%).
Table 1 Demographic data and predictors of response to hepatitis B vaccination
Total patients screened
(N = 1601)
Vaccine responders
(N = 59)
Vaccine non-responders
(N = 66)
p-Valuea
Age (years)
<24 54 4 1 NS
25—44 825 40 48 NS
45—59 682 13 17 NS
>60 40 2 0 NS
Sex
Male 1106 43 49 NS
Female 495 16 17 NS
Race
Black 1100 40 46 NS
White 436 16 25 NS
Hispanic 48 2 0 NS
Other 17 1 0 NS
Weight (kg)
<60 7 6 NS
61—90 33 45 NS
>90 17 15 NS
CD4+ T-cell count (cells/mm3)
<200 684 5 16 p = 0.068
201—350 12 19 NS
>350 878 (>201) 42 31 p = 0.006
Viral load (copies/ml)
<400 N/A 36 21 p = 0.001
<10 000 48 41 p = 0.0177
10 000—99 999 8 12 NS
>100 000 3 13 p = 0.0009
HAART
Yes N/A 48 49 NS
No 11 17 NS
Tobacco use
Yes 26 31 NS
No 25 25 NS
Unknown 8 10 NS
Hepatitis C-positive 15 13 NS
HAART, highly active antiretroviral therapy; NS, not significant; N/A, not available for all screened patients.
a The t-test was used for continuous variables and Fisher’s exact test or the Chi-square test was used for categorical variables.
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during the study period and were therefore excluded. Eight
hundred and six patients were not eligible for vaccination for
the following reasons: prior HBV infection was identified in
510 (63.3%), 93 (11.5%) had active or chronic HBV disease, 89
(11%) had the presence of HBcAb only, and 114 (14.1%) had
already received hepatitis B vaccination (Figure 1). No
adverse events related to the vaccine or its administration
were documented.
Of the 717 patients eligible to receive the hepatitis B
vaccine, 503 (70.2%) received at least one dose and 356 of the
717 (49.7%) completed the three-dose series. Of those who
had completed the HBV vaccination series, 125 patients had
HBsAb titers tested. Fifty-nine (47.2%) patients had detect-
able HBsAb (Figure 1). For this group of seroconverters, the
median CD4 count was 502 cells/mm3 (range 60—1225) andthe median HIV viral load was <400 copies/ml (range <50—
140). Fifteen patients were hepatitis C co-infected.
Sixty-six (52.8%) patients were HBsAb non-converters. The
median CD4 count of this group was 346 cells/mm3 (range 9—
1230), median HIV viral load was 5356 copies/ml (range
<50—>750 000), and thirteen were hepatitis C co-infected.
Three were not tested. Of these 66 patients who did not
respond to the initial series, 29 received a second vaccination
series (Figure 1). Nine of these patients had detectable
HBsAb after the second series, nine had no detectable HBsAb,
and 11 were not tested.
Response to HBV vaccination was significantly associated
with CD4 count greater than 350 cells/mm3 ( p = 0.006) and
undetectable HIV viral load ( p = 0.001). A CD4 count of
<200 cells/mm3 versus CD4 >350 cells/mm3 had an odds
ratio of four times greater of non-response (point esti-
e80 C.L. Bailey et al.mate = 4.3, confidence limits 1.3—14.5). However, response
was seen even at CD4 counts <50 cells/mm3. Lack of
response to vaccine was most significantly associated with
high HIV viral load (Figure 2). No association was detected
with age, race, weight, tobacco use, use of HAART, or
hepatitis C co-infection.
During the course of the study, in the group of 214 patients
who were eligible but not offered vaccination, sixteen
patients had documented exposure to HBVand seroconverted
(HBsAb-positive and HBcAb-positive). Four patients devel-
oped active hepatitis B. No patient that received full vaccine
series seroconverted or developed active HBV disease.
The documented reasons for not administering vaccina-
tion or completing the vaccination series were failure of the
provider to offer vaccination (85%), loss to follow-up (10%),
patient refusal (1.7%), and the remainder were unknown. The
average time from serologic screening to administration of
the first vaccine dose was 21.1 months (range 0—155
months). Reasoning for delaying vaccination was not well
documented. If cited, the providers most commonly
expressed concern for poor immunogenicity of the vaccine
at low CD4 counts. As a result, vaccination was either delayed
or not given at all during the study period, despite increased
CD4 count on follow-up visits.
Discussion
Because HIVand HBV share common routes of transmission, it
is recommended that all HIV-positive adults be screened for
HBV. Any person who is HBsAb, HBsAg, and HBcAb-negative
should receive the three-dose HBV vaccination series,
regardless of CD4 count or HIV viral load.2,9,10 Within 6
months after completion of the vaccination, the HBsAbFigure 2 Logistic regression model demonstrating HIV viral load as a
multivariate analysis included CD4 count, age, weight, use of HAART,
viral load was found to be an independent predictor of vaccine resshould be checked to verify adequate response. Those who
have HBsAb levels <10 mIU/ml should be given a second
vaccine series.11
Kellerman et al. looked at adults and adolescents infected
with HIV from 1998 to 2001.12 The highest rates of HBV
disease were seen in black subjects, alcohol users, intrave-
nous drug users, and subjects with AIDS, with a prevalence of
7.6%. An earlier study by Goldstein et al. showed similar risk
factors.13 Our cohort showed similar risk factors and a similar
prevalence of 6.1% of subjects with active or chronic HBV
disease at enrollment.
Larger studies in immunocompetent adults have shown
response rates to hepatitis B vaccination of 85—100%.
Decreased vaccine response has been seen due to obesity,
smoking, site or dose of vaccine, and gender.14 Prior studies of
the immunogenicity ofHBVvaccine inHIV-infected adults have
had small numbers and reported response rates varying from
0% to 87%.5—8,15—19 The association of seroconversion and CD4
count is not well defined. Some studies have shown higher
response rates associated with higher CD4 counts, but others
havenot (Table2).5—8,16—18 Improved response rates havebeen
shown with suppressed HIV viral load in some studies.5,16
The response rate to initial vaccination in our cohort was
47% of those vaccinated persons who had antibodies checked.
No vaccine recipient, regardless of antibody response,
acquired HBV during the study period. Higher CD4 counts
( p = 0.006) and undetectable HIV viral loads ( p = 0.001) at
the time of first vaccine dose were significantly associated
with seroconversion to HBsAb-positive.
Vaccination against HBV in an HIV-positive population has
the goal of preventing themorbidity andmortality associated
with clinical disease. HIV/HBV co-infection, especially in
persons with low CD4 counts, is associated with an increasedpredictor of non-response to the hepatitis B vaccine. (Note: The
sex, race, and presence of hepatitis C co-infection. Only the HIV
ponse.).
Table 2 Immunogenicity of hepatitis B vaccine in HIV-positive adults
Study CD4+ T-cell
count range
HIV viral load
(responders)
Number tested
(HBsAb-pos)
Response
(%)
Control number
tested (HIV-neg)
Control
response (%)
Collier et al. (1988) 18 CD4 >500 ND 8 7 (87.5) No
CD4 <500 12 4 (33.2)
Hess et al. (1989) 7 All stages ND 13 0 (0) 7 5 (71%)
Rey et al. (2000)8 CD4 >500 ND 8 7 (87.5) No
CD4 200—500 12 4 (33.3)
Wilson et al. (2001) 6 All stages <10 000 (9) 35 13 (37.1) 28 17 (60.1)
CD4 <400 >10 000 (4) 20 8
CD4 >400 15 5
Tedaldi et al. (2004) 5 All stages Range 1—5900 51 19 (37.2) No
Gandhi et al. (2005) 17 All stages ND 69 43 (62.3) No
Overton et al. (2005) 16 All stages <400 (23) 194 34 (17.5) No
CD4 <200 >400 (11) 40 5
CD4 200—500 84 16
CD4 >500 70 13
ND, not determined.
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cellular carcinoma. Chronic or active HBV infection also
appears to increase the hepatotoxicity of HAART.20
Many eligible HIV-positive adults do not receive HBV
vaccination. At screening 7.5% of our patients had evidence
or documentation of prior HBV immunization. In a prior study
of 342 homosexual males, only 9% had received HBV vaccina-
tion.21 There may be a number of reasons for missed vaccina-
tion including: (1) patient vaccination refusal, (2) loss to
follow-up, resulting in fewer than all three doses being
administered, (3) provider failure to screen or order the
administration of the full vaccination series, (4) patient
and/or provider failure to perceive the risk, (5) failure to
offer vaccination, due to the assumption it will have
decreased efficacy in patients with low CD4 counts, and
(6) financial barrier to vaccination, the vaccine may not be
reimbursed by the patient’s insurance company.
Our study was conducted in a clinic specializing in the care
of HIV-positive adults. All providers were trained in HIV care
or board-certified in infectious diseases. Despite 96.6% of
patients having HBV serologic screening at their initial visit,
49% of those patients eligible for vaccination completed the
three-dose series. Thirty percent of the vaccine eligible
patients did not receive a single vaccine dose. Other studies
have reported completion rates ranging from 29% to
50%.12,21—23 The reason for missed vaccination opportunity
in our study was most often provider failure to offer vaccina-Table 3 Significance of isolated hepatitis B core antibody
Study No. of
subjects
HBV-DNA
VL-positive (%)
Hepatit
C-posit
Lok et al. (1988) 30 32 ND ND
Ural et al. (2001) 29 48 ND ND
Alhababi et al. (2003) 27 155 6 (4)a 14 (9)
Gandhi et al. (2005) 17 29 ND 23 (79)
Neau et al. (2005) 24 160 1 (<1) (1/160)b 82 (51)
ND, not determined; VL, viral load.
a HBV-DNA <400 copies/ml.
b HBV viral DNA <200 copies ml.tion or missed completion of all three doses. Similar to other
studies, the most commonly cited reason for delaying vacci-
nation was concern for decreased immunogenicity in patients
with lower CD4 counts. In our study no correlation was
identified between missed vaccination and the number of
clinic visits or patient demographics. Because vaccinations
were provided without charge to the patient, cost was not
considered a barrier in our cohort.
Current guidelines do not recommend HBV vaccination for
persons with isolated HBcAb positivity.3 The significance of
HBcAb is unclear. Although it is seen in nearly all persons
exposed to hepatitis B, it does not appear protective against
infection. Furthermore, the presence of isolated HBcAb does
not distinguish between early acute infection, a chronic car-
rier statewith very low levels of HBsAg, remote HBV infections
with loss of HBsAb, or cross-reacting antibody (false-positive
test). Due to shared routes of transmission, patients are often
co-infected with HCV, and the presence of HCV may decrease
hepatitis B viral load.24—26 Other studies have also shown only
0—10% of patients with isolated HBcAb have detectable HBV-
DNA.24,27,28 HBV vaccination might benefit those patients who
have either lost HBsAb, and thus are at risk for reactivation or
re-infection, or those who have a false-positive HBcAb test.
There currently is nomeans of identifyingwhich persons are at
increased reactivation or infection risk.
We were unable to assess the rate of false-positive HBcAb
in our cohort because none of the patients with this findingis
ive (%)
Response to
vaccine dose 1 (%)
Response to 3
doses (%)
No response
(%)
15 (16) 18 (56) 9 (28)
24 (50) 43 (89) 5 (11)
ND ND ND
7 (24) 18 (63) 4 (13)
ND ND ND
e82 C.L. Bailey et al.had a hepatitis B viral load performed. Nearly half of these
patients (41/89) were co-infected with HCV. Past studies of
HBV vaccination of HIV-positive persons with isolated HBcAb
positivity and negative HBeAb have shown amnestic response
rates of 16—50% after the first vaccine dose with up to a 63%
seroconversion after the third dose (Table 3).17,24,27,29,30
Given the significant prevalence of hepatitis B infection in
HIV-infected populations, failure to implement the vaccina-
tion guidelines represents amissed opportunity to prevent the
morbidity and mortality associated with this disease. HBV
vaccination should be done in all HIV populations regardless
of CD4 count or viral load, although patients with a lower CD4
count or high HIV viremiamay have a lower seroresponse rate.
Current recommendations do not include vaccination of
persons seropositive for isolated HBcAb. Given the high rates
of hepatitis C co-infection in many HIV-infected patients,
that HBcAb may be falsely positive in persons co-infected
with hepatitis C, and that HBcAb is not protective against HBV
infection, vaccination should be considered.17,29,31 Further
studies are warranted to investigate the cost-effectiveness of
HBV-DNA screening for occult hepatitis B infection versus
vaccination in these populations.
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